Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Sales | 16,783,000 | 8,785,000 | 11,622,000 | 12,708,000 | 12,716,000 |
| Cost of Goods | 4,217,000 | 3,753,000 | 3,429,000 | 3,722,000 | 3,992,000 |
| Gross Profit | 8,813,000 | 8,785,000 | 8,193,000 | 8,986,000 | 8,724,000 |
| Operating Expenses | 6,169,000 | 6,373,000 | 5,841,000 | 6,242,000 | 6,901,000 |
| Operating Income | 2,644,000 | 2,412,000 | 2,352,000 | 2,744,000 | 1,823,000 |
| Interest Expense | 201,000 | 209,000 | 220,000 | 239,000 | 203,000 |
| Other Income | 116,000 | 207,000 | 156,000 | 116,000 | 139,000 |
| Pre-tax Income | 2,559,000 | 2,410,000 | 2,288,000 | 2,621,000 | 1,759,000 |
| Income Tax | 460,000 | 478,000 | 421,000 | 448,000 | 630,000 |
| Net Income Continuous | 2,099,000 | 1,932,000 | 1,867,000 | 2,173,000 | 1,129,000 |
| Minority Interests | 5,000 | -3,000 | N/A | -3,000 | 4,000 |
| Net Income | $2,094,000 | $1,935,000 | $1,867,000 | $2,176,000 | $1,125,000 |
| EPS Basic Total Ops | 0.92 | 0.85 | 0.82 | 0.96 | 0.51 |
| EPS Basic Continuous Ops | 0.93 | 0.85 | 0.82 | 0.96 | 0.50 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | N/A | 0.02 |
| EPS Diluted Total Ops | 0.92 | 0.84 | 0.81 | 0.95 | 0.50 |
| EPS Diluted Continuous Ops | 0.92 | 0.84 | 0.81 | 0.95 | 0.49 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | N/A | 0.01 |
| EBITDA(a) | $7,945,000 | $254,000 | $2,352,000 | $2,744,000 | $3,771,000 |